111 related articles for article (PubMed ID: 28793041)
1. Experimental study of peripheral-blood pro-surfactant protein B for screening non-small cell lung cancer.
He Y; Jiang Z; Tong F; Li M; Yin X; Hu S; Wang L
Acta Cir Bras; 2017 Jul; 32(7):568-575. PubMed ID: 28793041
[TBL] [Abstract][Full Text] [Related]
2. Pro-surfactant protein B as a biomarker for lung cancer prediction.
Sin DD; Tammemagi CM; Lam S; Barnett MJ; Duan X; Tam A; Auman H; Feng Z; Goodman GE; Hanash S; Taguchi A
J Clin Oncol; 2013 Dec; 31(36):4536-43. PubMed ID: 24248694
[TBL] [Abstract][Full Text] [Related]
3. Gene polymorphisms of SFTPB rs7316, rs9752 and PAOX rs1046175 affect the diagnostic value of plasma Pro-SFTPB and DAS in Chinese Han non-small-cell lung cancer patients.
Wang K; Huang Q; Zhao G; Yang J; Yang K; Huang Y
J Cell Biochem; 2019 Sep; 120(9):14804-14812. PubMed ID: 31016788
[TBL] [Abstract][Full Text] [Related]
4. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.
Wikoff WR; Hanash S; DeFelice B; Miyamoto S; Barnett M; Zhao Y; Goodman G; Feng Z; Gandara D; Fiehn O; Taguchi A
J Clin Oncol; 2015 Nov; 33(33):3880-6. PubMed ID: 26282655
[TBL] [Abstract][Full Text] [Related]
5. Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer.
Ruhaak LR; Stroble C; Dai J; Barnett M; Taguchi A; Goodman GE; Miyamoto S; Gandara D; Feng Z; Lebrilla CB; Hanash S
Cancer Prev Res (Phila); 2016 Apr; 9(4):317-23. PubMed ID: 26813970
[TBL] [Abstract][Full Text] [Related]
6. Screening for Lung Cancer: What Comes Next?
Peled N; Ilouze M
J Clin Oncol; 2015 Nov; 33(33):3847-8. PubMed ID: 26304887
[No Abstract] [Full Text] [Related]
7. Plasma pro-surfactant protein B and lung function decline in smokers.
Leung JM; Mayo J; Tan W; Tammemagi CM; Liu G; Peacock S; Shepherd FA; Goffin J; Goss G; Nicholas G; Tremblay A; Johnston M; Martel S; Laberge F; Bhatia R; Roberts H; Burrowes P; Manos D; Stewart L; Seely JM; Gingras M; Pasian S; Tsao MS; Lam S; Sin DD;
Eur Respir J; 2015 Apr; 45(4):1037-45. PubMed ID: 25614175
[TBL] [Abstract][Full Text] [Related]
8. Prediction of lung cancer risk using circulating pro-surfactant protein B and high-sensitivity C-reactive protein among Egyptian workers in the rubber industry.
Mourad BH
Toxicol Ind Health; 2020 Apr; 36(4):237-249. PubMed ID: 32419650
[TBL] [Abstract][Full Text] [Related]
9. Circulating pro-surfactant protein B as a risk biomarker for lung cancer.
Taguchi A; Hanash S; Rundle A; McKeague IW; Tang D; Darakjy S; Gaziano JM; Sesso HD; Perera F
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1756-61. PubMed ID: 23897585
[TBL] [Abstract][Full Text] [Related]
10. [The value of circulating tumor cells detected by chromosome centromere probe identification in diagnosis of non-small cell lung cancer].
Shen Q; Shen LS; Chen Q; Zhou JY; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):772-777. PubMed ID: 30347548
[No Abstract] [Full Text] [Related]
11. Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.
Kargi A; Bisgin A; Yalcin AD; Kargi AB; Sahin E; Gumuslu S
Asian Pac J Cancer Prev; 2013; 14(8):4819-22. PubMed ID: 24083751
[TBL] [Abstract][Full Text] [Related]
12. Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood.
Yamamoto O; Takahashi H; Hirasawa M; Chiba H; Shiratori M; Kuroki Y; Abe S
Respir Med; 2005 Sep; 99(9):1164-74. PubMed ID: 16085219
[TBL] [Abstract][Full Text] [Related]
13. Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: a case-control study.
Shang AQ; Xie YN; Wang J; Sun L; Wei J; Lu WY; Lan JY; Wang WW; Wang L; Wang LL
Neoplasma; 2017; 64(3):453-459. PubMed ID: 28253725
[TBL] [Abstract][Full Text] [Related]
14. Serum microRNA biomarkers for detection of non-small cell lung cancer.
Hennessey PT; Sanford T; Choudhary A; Mydlarz WW; Brown D; Adai AT; Ochs MF; Ahrendt SA; Mambo E; Califano JA
PLoS One; 2012; 7(2):e32307. PubMed ID: 22389695
[TBL] [Abstract][Full Text] [Related]
15. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.
Maeda J; Higashiyama M; Imaizumi A; Nakayama T; Yamamoto H; Daimon T; Yamakado M; Imamura F; Kodama K
BMC Cancer; 2010 Dec; 10():690. PubMed ID: 21176209
[TBL] [Abstract][Full Text] [Related]
16. Whole blood microRNA expression may not be useful for screening non-small cell lung cancer.
Patnaik SK; Kannisto ED; Mallick R; Vachani A; Yendamuri S
PLoS One; 2017; 12(7):e0181926. PubMed ID: 28742859
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
18. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
19. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Sun N; Chen Z; Tan F; Zhang B; Yao R; Zhou C; Li J; Gao Y; Liu Z; Tan X; Zhou F; He MY; Shao K; Li N; Qiu B; Sun J; Yu Y; Wang S; Zhao Y; Shi X; He J
Clin Cancer Res; 2013 Sep; 19(18):5136-45. PubMed ID: 24046070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
